CAJ | 학술논문

目的： COPD 是一种发病率和病死率较高的重要疾病,近年来在疾病严重程度评估方面也提出了新的标准,本研究的目的在于探讨 COPD 患者疾病严重程度与血浆抗菌肽 LL-37水平的关系。方法研究对象为2012年10月至2013年4月北京医院就诊的 COPD 患者和同期健康体检者。根据COPD 的疾病严重程度,将患者分为低风险组和高风险组。应用酶联免疫吸附试验(ELISA)法检测各组血浆中 LL-37水平。比较各组间 LL-37水平的差异,并探讨 LL-37水平与疾病严重程度评价指标之间的关系。结果共纳入 COPD 患者44例和同期健康体检者20例。根据疾病严重程度,将 COPD 患者分为低风险组22例和高风险组22例。对照组、低风险组、高风险组的血浆 LL-37水平分别为(19.8±4.8)μg/L、(19.9±4.3)μg/L、(16.1±3.6)μg/L,各组间比较差异有统计学意义(F =5.611,P =0.006)。对照组血浆 LL-37水平与低风险组比较,差异无统计学意义(平均差值-0.08,95% CI -2.53~2.71,P =0.947)。高风险组血浆 LL-37水平明显低于对照组(平均差值-3.69,95% CI -6.31~-1.07,P =0.007)和低风险组(平均差值-3.78,95% CI -6.33~-1.22,P =0.004),差异有统计学意义。COPD 患者血浆 LL-37水平与 FEV1、FEV1% pred、FEV1/FVC 之间均呈显著正相关,相关系数分别为0.460、0.532、0.515,P 值分别为0.006、0.001、0.012。COPD 患者血浆 LL-37水平与改良英国MRC 呼吸困难指数之间呈显著负相关(r =-0.347,P =0.033)。结论 COPD 患者血浆中的 LL-37水平与病情严重程度,尤其是呼吸困难症状和气道阻塞程度相关。
목적： COPD 시일충발병솔화병사솔교고적중요질병,근년래재질병엄중정도평고방면야제출료신적표준,본연구적목적재우탐토 COPD 환자질병엄중정도여혈장항균태 LL-37수평적관계。방법연구대상위2012년10월지2013년4월북경의원취진적 COPD 환자화동기건강체검자。근거COPD 적질병엄중정도,장환자분위저풍험조화고풍험조。응용매련면역흡부시험(ELISA)법검측각조혈장중 LL-37수평。비교각조간 LL-37수평적차이,병탐토 LL-37수평여질병엄중정도평개지표지간적관계。결과공납입 COPD 환자44례화동기건강체검자20례。근거질병엄중정도,장 COPD 환자분위저풍험조22례화고풍험조22례。대조조、저풍험조、고풍험조적혈장 LL-37수평분별위(19.8±4.8)μg/L、(19.9±4.3)μg/L、(16.1±3.6)μg/L,각조간비교차이유통계학의의(F =5.611,P =0.006)。대조조혈장 LL-37수평여저풍험조비교,차이무통계학의의(평균차치-0.08,95% CI -2.53~2.71,P =0.947)。고풍험조혈장 LL-37수평명현저우대조조(평균차치-3.69,95% CI -6.31~-1.07,P =0.007)화저풍험조(평균차치-3.78,95% CI -6.33~-1.22,P =0.004),차이유통계학의의。COPD 환자혈장 LL-37수평여 FEV1、FEV1% pred、FEV1/FVC 지간균정현저정상관,상관계수분별위0.460、0.532、0.515,P 치분별위0.006、0.001、0.012。COPD 환자혈장 LL-37수평여개량영국MRC 호흡곤난지수지간정현저부상관(r =-0.347,P =0.033)。결론 COPD 환자혈장중적 LL-37수평여병정엄중정도,우기시호흡곤난증상화기도조새정도상관。
Objective To explore the relationship between cathelicidin LL-37 levels in plasma and disease severity in chronic obstructive pulmonary disease (COPD)patients.Methods COPD patients and normal subjects were recruited at Beijing Hospital from October 2012 to April 2013 for this study.COPD patients were divided into low risk group and high risk group,depending on disease severity.The LL-37 concentrations in plasma were measured by enzyme-linked immunosorbent assay (ELISA)kit.To explore the difference in LL-37 levels between groups and the relationship between LL-37 levels in plasma and disease severity indexes.Results Forty-four COPD patients and 20 normal subjects (control group)were recruited,COPD patients were divided into low risk group (22 cases)and high risk group (22 cases), depending on disease severity.The plasma LL-37 levels in control group,low risk group and high risk group were (1 9.8 ± 4.8 )μg/L,(1 9.9 ± 4.3 )μg/L and (1 6.1 ± 3.6 )μg/L,there was significant difference between groups (F = 5.61 1,P =0.006).There was no differences between low risk group and control group in the plasma levels of LL-37 (mean difference -0.08,95% CI -2.53 ~ 2.71,P =0.947).The plasma levels of LL-37 in high risk group was significantly lower than control group (mean difference -3.69,95% CI -6.31~-1.07,P = 0.007 )and low risk group (mean difference -3.78, 95% CI -6.33 ~ -1.22,P = 0.004 ). The concentrations of LL-37 in plasma were significantly correlated with FEV1 (r =0.460,P =0.006),FEV1 %pred (r =0.532,P =0.001),FEV1/FVC (r =0.5 1 5,P =0.012 )and modified medical research council score (r = -0.347,P = 0.033 )in COPD patients.Conclusions The concentrations of LL-37 in plasma was correlated with disease severity, especially with dyspnea severity and airway obstructive severity in COPD patients.